{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-251740","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2021-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.517310+00:00","generated_at":"2026-06-29T08:42:14.847013+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Mirum appoints William Fairey to board, replacing Tiba Aynechi","bullets":["Tiba Aynechi resigned from the board effective August 19, 2021; no dispute or disagreement cited.","William Fairey appointed to board effective August 19, 2021; will serve as Class I director through 2023 annual meeting.","Fairey granted stock option for 34,000 shares vesting over 3 years; annual cash retainer of $40K plus $10K for Audit Committee.","Fairey brings ~30 years biotech commercial experience; previously at MyoKardia, ChemoCentryx, and Actelion.","Company preparing for first U.S. product launch; board also appointed Carol Brosgart and Patrick Heron to committees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-251740","json":"https://secwatch.observer/filing/0001193125-21-251740.json","markdown":"https://secwatch.observer/filing/0001193125-21-251740.md","text":"https://secwatch.observer/filing/0001193125-21-251740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312521251740/0001193125-21-251740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312521251740/d216866d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:42:14.847013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0c006755c","claim":"Tiba Aynechi resigned as Director at Mirum Pharmaceuticals, Inc..","evidence_excerpt":"On August 16, 2021, Tiba Aynechi, Ph.D. notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company, effective August 19, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312521251740/0001193125-21-251740-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f87a822430","claim":"William Fairey was appointed as Director at Mirum Pharmaceuticals, Inc..","evidence_excerpt":"On August 19, 2021, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed William Fairey to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312521251740/0001193125-21-251740-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}